A nurse is caring for a patient who has been receiving continuous intravenous heparin therapy for deep vein thrombosis. The patient's most recent activated partial thromboplastin time (aPTT) is 120 seconds (normal range: 25-35 seconds). The nurse notices the patient has developed new bruising on both arms and reports feeling dizzy when standing up. Which action should the nurse take first?

aPTT of 120 seconds indicates excessive anticoagulation with bleeding risk; stopping heparin and notifying provider is the priority action. Other options could worsen bleeding or delay intervention.

Understanding the Clinical Scenario

The patient is on continuous IV heparin for deep vein thrombosis. The aPTT is 120 seconds, which is critically supratherapeutic when compared to the normal range of 25-35 seconds. The clinical presentation is highly concerning: new, spontaneous bruising on both arms and orthostatic dizziness. These signs point toward a serious hemorrhagic complication, with the dizziness potentially indicating hypovolemia from active, unseen internal bleeding.

Analyzing the aPTT and Clinical Signs

Unfractionated heparin (UFH) is a high-risk medication that requires vigilant monitoring, most commonly via the activated partial thromboplastin time (aPTT). The aPTT reflects the intrinsic and common coagulation pathways, which heparin prolongs ^[1]. A therapeutic aPTT range is typically 1.5 to 2.5 times the control value. An aPTT of 120 seconds is far beyond this therapeutic window and indicates a profound anticoagulant effect. This laboratory value, when combined with the physical assessment findings of new ecchymoses and dizziness, confirms that the patient is actively bleeding. The dizziness upon standing is a critical "red flag" for hemodynamic instability, likely due to acute blood loss.

Priority Action and Rationale

The nurse's immediate priority is patient safety. The most direct and effective action to prevent further harm is to stop the administration of the causative agent.

- Stop the heparin infusion: The continuous infusion is the direct source of the excessive anticoagulation. Discontinuing it immediately halts the introduction of more heparin into the patient's system, which is the first step in managing an acute bleed. The half-life of IV UFH is relatively short (approximately 1-2 hours), so stopping the infusion allows the body to begin clearing the drug.
- Notify the healthcare provider: This is a critical component of the same action. The provider must be informed immediately of the critical aPTT value and the patient's deteriorating clinical status to prescribe definitive reversal agents and order further diagnostic tests and interventions.

Why the Other Options Are Incorrect

- Option 1: Increase the heparin infusion rate. This is contraindicated and dangerous. The aPTT is already critically high, and the patient is showing signs of active bleeding. Increasing the dose would exacerbate the hemorrhage and could be fatal.
- Option 2: Continue the current heparin dose and recheck aPTT in 6 hours. This is a passive and unsafe action. A critically high aPTT with active bleeding signs is a medical emergency that requires immediate intervention, not watchful waiting. Delaying action for 6 hours would allow the hemorrhage to progress unchecked.
- Option 3: Administer protamine sulfate immediately. While protamine sulfate is the specific reversal agent for UFH, it is not the nurse's first independent action. Protamine administration requires a healthcare provider's order. The nurse's immediate, independent action to mitigate harm is to stop the source of the problem—the heparin drip—and then rapidly seek the order for the antidote. The sequence is critical: stop the offending agent, then prepare to administer the reversal agent as prescribed.

Connecting to Laboratory Monitoring Challenges

This scenario highlights why aPTT monitoring, while standard, can be challenging. The review by Reardon et al. notes that aPTT results can be influenced by various factors, including underlying illness, which is a known pitfall in monitoring ^[1]. In critically ill patients, disease-related alterations in the coagulation system can directly affect aPTT, making interpretation complex . This underscores the importance of always correlating the laboratory value with the patient's clinical presentation. In this case, the grossly abnormal aPTT is validated by the physical evidence of bleeding, leaving no ambiguity about the need for immediate action. The study by Mirus et al. explores alternative monitoring methods like anti-Xa and viscoelastic testing precisely because of these aPTT limitations, especially when 24/7 availability of anti-Xa is lacking . Similarly, Nishida et al. investigated a thromboelastography-based method for monitoring heparin in a pediatric ICU, acknowledging that misestimation of heparin effect using aPTT can risk bleeding complications . This patient's presentation is a direct example of such a bleeding complication from supratherapeutic heparin.